Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients

H. H. Garcia; R. M.E. Parkhouse; R. H. Gilman; T. Montenegro; T. Bernal; S. M. Martinez; A. E. Gonzalez; V. C.W. Tsang; L. J.S. Harrison

doi:10.1016/S0035-9203(00)90228-1

Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients

H. H. Garcia, R. M.E. Parkhouse, R. H. Gilman, T. Montenegro, T. Bernal, S. M. Martinez, A. E. Gonzalez, V. C.W. Tsang, L. J.S. Harrison

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Abstract

The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum. The assay displayed 85% diagnostic sensitivity, detecting 39 of 46 NCC cases. Only patients with a single viable cyst or only enhancing lesions (degenerating parasites) were seronegative. Specificity of the assay was 92% (23/25) when tested in healthy Peruvian volunteers. In 'cured' patients, in whom all parasites died after ABZ therapy, parasite antigen levels fell sharply by 3 months post treatment. This pattern was not observed in patients refractory to treatment. The sensitivity of the assay with serum samples, and its ability to identify successfully treated patients, make this monoclonal antibody-based ELISA the test of choice for the follow-up of NCC cases.

Original language	English
Pages (from-to)	673-676
Number of pages	4
Journal	Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume	94
Issue number	6
DOIs	https://doi.org/10.1016/S0035-9203(00)90228-1
State	Published - 2000

Bibliographical note

Funding Information:
all the personnelo f the cysticercosilsa boratoryo f the Institute National de CienciasN eurologicasf or help in samplem anage-ment and data collection.T his study was funded in part by grants CT95-0002 from the INCO-DC programmeo f the European Union, FD-R-001107 from the Food and Drug Administration,a nd numbersU 19-A145431,T WOO598,a nd R03-AI-42037 from the National Institutesf or Health, USA. The authorsa lsoa cknowledgeth eBritish Council for supporti n the form of a Higher Education Link Project between the Universityo f Edinburgha ndt heU niversidadP eruanaC ayetano Heredia.

Keywords

Albendazole
Antigen detection
Chemotherapy
ELISA
Follow-up
Neurocysticercosis
Peru
Taenia solium

Access to Document

10.1016/S0035-9203(00)90228-1

Cite this

Garcia, H. H., Parkhouse, R. M. E., Gilman, R. H., Montenegro, T., Bernal, T., Martinez, S. M., Gonzalez, A. E., Tsang, V. C. W., & Harrison, L. J. S. (2000). Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 94(6), 673-676. https://doi.org/10.1016/S0035-9203(00)90228-1

@article{a2c741a7b44c4dd782809baf785f604a,

title = "Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients",

abstract = "The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum. The assay displayed 85% diagnostic sensitivity, detecting 39 of 46 NCC cases. Only patients with a single viable cyst or only enhancing lesions (degenerating parasites) were seronegative. Specificity of the assay was 92% (23/25) when tested in healthy Peruvian volunteers. In 'cured' patients, in whom all parasites died after ABZ therapy, parasite antigen levels fell sharply by 3 months post treatment. This pattern was not observed in patients refractory to treatment. The sensitivity of the assay with serum samples, and its ability to identify successfully treated patients, make this monoclonal antibody-based ELISA the test of choice for the follow-up of NCC cases.",

keywords = "Albendazole, Antigen detection, Chemotherapy, ELISA, Follow-up, Neurocysticercosis, Peru, Taenia solium",

author = "Garcia, {H. H.} and Parkhouse, {R. M.E.} and Gilman, {R. H.} and T. Montenegro and T. Bernal and Martinez, {S. M.} and Gonzalez, {A. E.} and Tsang, {V. C.W.} and Harrison, {L. J.S.}",

note = "Funding Information: all the personnelo f the cysticercosilsa boratoryo f the Institute National de CienciasN eurologicasf or help in samplem anage-ment and data collection.T his study was funded in part by grants CT95-0002 from the INCO-DC programmeo f the European Union, FD-R-001107 from the Food and Drug Administration,a nd numbersU 19-A145431,T WOO598,a nd R03-AI-42037 from the National Institutesf or Health, USA. The authorsa lsoa cknowledgeth eBritish Council for supporti n the form of a Higher Education Link Project between the Universityo f Edinburgha ndt heU niversidadP eruanaC ayetano Heredia.",

year = "2000",

doi = "10.1016/S0035-9203(00)90228-1",

language = "Ingl{\'e}s",

volume = "94",

pages = "673--676",

journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",

issn = "0035-9203",

publisher = "Oxford University Press",

number = "6",

}

Garcia, HH, Parkhouse, RME, Gilman, RH, Montenegro, T, Bernal, T, Martinez, SM, Gonzalez, AE, Tsang, VCW & Harrison, LJS 2000, 'Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients', Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 6, pp. 673-676. https://doi.org/10.1016/S0035-9203(00)90228-1

TY - JOUR

T1 - Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients

AU - Garcia, H. H.

AU - Parkhouse, R. M.E.

AU - Gilman, R. H.

AU - Montenegro, T.

AU - Bernal, T.

AU - Martinez, S. M.

AU - Gonzalez, A. E.

AU - Tsang, V. C.W.

AU - Harrison, L. J.S.

N1 - Funding Information: all the personnelo f the cysticercosilsa boratoryo f the Institute National de CienciasN eurologicasf or help in samplem anage-ment and data collection.T his study was funded in part by grants CT95-0002 from the INCO-DC programmeo f the European Union, FD-R-001107 from the Food and Drug Administration,a nd numbersU 19-A145431,T WOO598,a nd R03-AI-42037 from the National Institutesf or Health, USA. The authorsa lsoa cknowledgeth eBritish Council for supporti n the form of a Higher Education Link Project between the Universityo f Edinburgha ndt heU niversidadP eruanaC ayetano Heredia.

PY - 2000

Y1 - 2000

N2 - The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum. The assay displayed 85% diagnostic sensitivity, detecting 39 of 46 NCC cases. Only patients with a single viable cyst or only enhancing lesions (degenerating parasites) were seronegative. Specificity of the assay was 92% (23/25) when tested in healthy Peruvian volunteers. In 'cured' patients, in whom all parasites died after ABZ therapy, parasite antigen levels fell sharply by 3 months post treatment. This pattern was not observed in patients refractory to treatment. The sensitivity of the assay with serum samples, and its ability to identify successfully treated patients, make this monoclonal antibody-based ELISA the test of choice for the follow-up of NCC cases.

AB - The efficacy of albendazole (ABZ) treatment for human neurocysticercosis (NCC) was assessed by using a monoclonal antibody-based parasite antigen detection ELISA which specifically detects the products of living cysticerci in human serum. The assay displayed 85% diagnostic sensitivity, detecting 39 of 46 NCC cases. Only patients with a single viable cyst or only enhancing lesions (degenerating parasites) were seronegative. Specificity of the assay was 92% (23/25) when tested in healthy Peruvian volunteers. In 'cured' patients, in whom all parasites died after ABZ therapy, parasite antigen levels fell sharply by 3 months post treatment. This pattern was not observed in patients refractory to treatment. The sensitivity of the assay with serum samples, and its ability to identify successfully treated patients, make this monoclonal antibody-based ELISA the test of choice for the follow-up of NCC cases.

KW - Albendazole

KW - Antigen detection

KW - Chemotherapy

KW - ELISA

KW - Follow-up

KW - Neurocysticercosis

KW - Peru

KW - Taenia solium

UR - http://www.scopus.com/inward/record.url?scp=0033659834&partnerID=8YFLogxK

U2 - 10.1016/S0035-9203(00)90228-1

DO - 10.1016/S0035-9203(00)90228-1

M3 - Artículo

C2 - 11198654

AN - SCOPUS:0033659834

SN - 0035-9203

VL - 94

SP - 673

EP - 676

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

IS - 6

ER -

Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this